<p>药明康德（Paychex (PAYX)）已举行第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>药明康德最新的财报电话会议描绘了在创新支撑下的强劲增长，尽管管理层承认每位客户的收入和某些业务线存在一些疲软。管理层的语气充满信心，强调了强劲的收入和利润增长、Paycor 收购的有效整合，以及来自人工智能投资的早期实质性好处，同时对管理解决方案、Paycor 的独立增长和保险业务的挑战保持透明。</p>
<h2>强劲的收入和营业收入增长</h2>
<p>药明康德交出了出色的季度业绩，收入同比增长 18% 达到 16 亿美元，调整后的营业收入增长 21%。管理层将此归功于更高的生产力、严谨的执行和效率提升，其中许多是由技术和人工智能整合驱动的。这种强劲的收入扩张和更快的利润增长的结合表明运营杠杆的改善，并支持公司在人力资本管理和薪资领域作为更具韧性的企业之一的定位。</p>
<h2>人工智能和创新进展</h2>
<p>电话会议的一个核心主题是药明康德在人工智能方面的快速进展。公司强调推出了一款基于 GenAI 的就业法律和合规平台，旨在简化客户的复杂法规，以及一款正在申请专利的人工智能驱动的知识网格系统，增强信息在业务中的访问和使用方式。管理层将这些工具视为竞争差异化因素和内部生产力的驱动因素，旨在在结构上降低服务成本的同时提供更好的客户结果。</p>
<h2>Paycor 整合成功</h2>
<p>Paycor 收购正在成为一个关键的战略支柱，管理层强调整合进展超出计划。药明康德已经超过了其成本协同目标，并预计在 2026 财年实现约 1 亿美元的成本协同，同时也在朝着收入协同目标迈进。合并平台旨在扩大药明康德的覆盖范围，扩展其产品组合，并创造交叉销售机会，尽管 Paycor 本身在短期内的增长有所放缓，但仍支持长期增长的叙述。</p>
<h2>强劲的 PEO 业务表现</h2>
<p>药明康德的 PEO 业务仍然是一个亮点，工作场所员工实现中个位数增长，客户留存率接近创纪录水平。管理层提到对捆绑的人力资源、福利和合规服务的强劲需求，推动了稳健的收入增长和改善的可见性。PEO 部门的表现提供了多样化和稳定性，帮助抵消保险等更具周期性或利率敏感领域的波动，并强化了公司为寻求全方位人力资源解决方案的小型和中型雇主提供的价值主张。</p>
<h2>提高盈利预期</h2>
<p>尽管某些领域存在疲软，药明康德提高了其盈利展望。调整后的稀释每股收益预计将增长 10-11%，将范围从之前的 9-11% 上调。尽管本季度 GAAP 稀释每股收益下降 4% 至 1.10 美元，但调整后的稀释每股收益增长 11% 至 1.26 美元，反映出在排除整合和其他非经常性项目后强劲的基础表现。更高的指引表明管理层对运营效率和协同实现将超过当前逆风的信心。</p>
<h2>每位客户的收入疲软</h2>
<p>电话会议上提到的一个担忧是每位客户的收入低于预期。管理层将此主要归因于较小的交易规模和销售时初始产品附加率较低。尽管客户基础依然稳固，但在当前环境中，获取每位客户更多的消费份额已证明具有挑战性。药明康德旨在通过增强交叉销售努力、改善前线销售执行以及利用其人工智能驱动的工具来展示更多价值，鼓励客户逐步采用更广泛的服务组合来解决这一问题。</p>
<h2>管理解决方案中的挑战</h2>
<p>在管理解决方案中，作为核心收入驱动因素，每位客户的收入增长也因同样的小交易和前期产品附加较少而略显疲软。这表明，尽管对基本薪资和人力资源服务的需求健康，但客户在初期对附加更多模块持谨慎态度。投资者将关注药明康德是否能够在这一领域重新激活追加销售，并将初始关系转化为更深入、更高利润的合作关系，随着经济条件的演变。</p>
<h2>Paycor 增长担忧</h2>
<p>尽管 Paycor 整合正在带来协同效益，但 Paycor 自身的有机增长略低于之前的预期，预计增长为 8-9%。管理层将情况描述为复杂，指出整合相关的干扰和客户流动是导致因素。尽管这一略微放缓的轨迹值得关注，但药明康德强调交易的长期战略逻辑依然完好，协调平台和市场策略最终应支持合并实体的更健康、更可持续的增长。</p>
<h2>保险代理表现拖累</h2>
<p>保险代理业务对业绩造成了显著拖累，受到工人赔偿率疲软和健康福利业务量下降的压力。这些市场驱动的逆风减少了收入，并抑制了整体业务部门的表现。虽然这并不是 Paychex 故事的核心，但保险部门的疲软凸显了公司对费率环境和福利趋势的暴露，并强化了高增长的 PEO 和技术驱动的人力资源服务在推动整体公司业绩方面的重要性。</p>
<h2>指引与前瞻展望</h2>
<p>展望未来，Paychex 重申了其 2026 财年的展望，并对其发展轨迹表示信心。管理层预计今年与 Paycor 相关的成本协同效应约为 1 亿美元，并继续瞄准通过交叉销售和平台整合实现的收入协同效应。调整后的稀释每股收益增长现已预计为 10-11%，得益于本季度 18% 的收入增长、管理解决方案收入的 21% 增长，以及调整后营业收入的 21% 增加。公司认为其人工智能举措，包括知识网格系统和 GenAI 合规平台，是未来提高效率和创造客户价值的关键杠杆，使 Paychex 在某些业务线面临短期压力的情况下仍能实现可持续增长。</p>
<p>总之，Paychex 的财报电话会议将强劲的执行力与对当前挑战的审慎现实相结合。收入和调整后的利润以健康的速度增长，Paycor 的整合超出计划交付了协同效应，人工智能投资也开始重塑运营。同时，客户每单位收入的疲软、Paycor 增长略显乏力以及保险业务的逆风仍然是需要关注的领域。总体而言，语气乐观，管理层依靠创新和整合带来的好处来支持持续的盈利增长和长期的股东价值。</p>

沛齐

<p>Paychex 第二季度的财报电话会议强调了尽管收入有所疲软，但仍然受益于人工智能和创新的强劲增长。收入增长了 18%，达到 16 亿美元，营业收入增长了 21%。会议强调了人工智能的进步和成功的 Paycor 整合。PEO 业务表现强劲，盈利预期上升。面临的挑战包括每位客户的收入下降和 Paycor 的增长放缓。管理层对通过运营效率和协同效应的实现来克服这些障碍保持信心</p>

<p>Paychex ((PAYX)) has held its Q2 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>药明康德（Paychex (PAYX)）已举行第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Paychex’s latest earnings call painted a picture of robust growth underpinned by innovation, even as management acknowledged pockets of softness in revenue per client and certain business lines. Management’s tone was confident, emphasizing strong top- and bottom-line gains, effective integration of the Paycor acquisition, and tangible early benefits from AI investments, while remaining transparent about challenges in Management Solutions, Paycor’s standalone growth, and insurance operations.</p>
<div class="lb-trans"><p>药明康德最新的财报电话会议描绘了在创新支撑下的强劲增长，尽管管理层承认每位客户的收入和某些业务线存在一些疲软。管理层的语气充满信心，强调了强劲的收入和利润增长、Paycor 收购的有效整合，以及来自人工智能投资的早期实质性好处，同时对管理解决方案、Paycor 的独立增长和保险业务的挑战保持透明。</p>
</div><h2>Strong Revenue and Operating Income Growth</h2>
<div class="lb-trans"><h2>强劲的收入和营业收入增长</h2>
</div><p>Paychex delivered a standout quarter, with revenue up 18% year-over-year to $1.6 billion and adjusted operating income climbing 21%. Management credited higher productivity, disciplined execution, and efficiency gains, many of them driven by technology and AI integration. This combination of strong revenue expansion and even faster profit growth suggests improving operating leverage and supports the company’s positioning as one of the more resilient names in the human capital management and payroll space.</p>
<div class="lb-trans"><p>药明康德交出了出色的季度业绩，收入同比增长 18% 达到 16 亿美元，调整后的营业收入增长 21%。管理层将此归功于更高的生产力、严谨的执行和效率提升，其中许多是由技术和人工智能整合驱动的。这种强劲的收入扩张和更快的利润增长的结合表明运营杠杆的改善，并支持公司在人力资本管理和薪资领域作为更具韧性的企业之一的定位。</p>
</div><h2>AI and Innovation Advancements</h2>
<div class="lb-trans"><h2>人工智能和创新进展</h2>
</div><p>A central theme of the call was Paychex’s rapid progress in artificial intelligence. The company highlighted the launch of a GenAI-powered employment law and compliance platform designed to simplify complex regulations for clients, as well as a patent-pending AI-powered knowledge mesh system that enhances how information is accessed and used across the business. Management framed these tools as both a competitive differentiator and a driver of internal productivity, aiming to deliver better client outcomes while structurally lowering cost-to-serve over time.</p>
<div class="lb-trans"><p>电话会议的一个核心主题是药明康德在人工智能方面的快速进展。公司强调推出了一款基于 GenAI 的就业法律和合规平台，旨在简化客户的复杂法规，以及一款正在申请专利的人工智能驱动的知识网格系统，增强信息在业务中的访问和使用方式。管理层将这些工具视为竞争差异化因素和内部生产力的驱动因素，旨在在结构上降低服务成本的同时提供更好的客户结果。</p>
</div><h2>Successful Paycor Integration</h2>
<div class="lb-trans"><h2>Paycor 整合成功</h2>
</div><p>The Paycor acquisition is emerging as a key strategic pillar, and management stressed that integration is tracking ahead of plan. Paychex has already exceeded its cost synergy targets and now expects about $100 million in cost synergies in fiscal 2026, while also progressing toward its revenue synergy goals. The combined platform is intended to broaden Paychex’s reach, expand its product suite, and create cross-sell opportunities, supporting the longer-term growth narrative despite some near-term growth moderation at Paycor itself.</p>
<div class="lb-trans"><p>Paycor 收购正在成为一个关键的战略支柱，管理层强调整合进展超出计划。药明康德已经超过了其成本协同目标，并预计在 2026 财年实现约 1 亿美元的成本协同，同时也在朝着收入协同目标迈进。合并平台旨在扩大药明康德的覆盖范围，扩展其产品组合，并创造交叉销售机会，尽管 Paycor 本身在短期内的增长有所放缓，但仍支持长期增长的叙述。</p>
</div><h2>Strong PEO Business Performance</h2>
<div class="lb-trans"><h2>强劲的 PEO 业务表现</h2>
</div><p>Paychex’s PEO business remained a bright spot, posting mid-single-digit growth in worksite employees and near-record client retention. Management cited strong demand for bundled HR, benefits, and compliance services, which drove solid revenue growth and improved visibility. The PEO segment’s performance provides diversification and stability, helping offset volatility in more cyclical or rate-sensitive areas such as insurance, and reinforces the company’s value proposition for small and mid-sized employers seeking full-service HR solutions.</p>
<div class="lb-trans"><p>药明康德的 PEO 业务仍然是一个亮点，工作场所员工实现中个位数增长，客户留存率接近创纪录水平。管理层提到对捆绑的人力资源、福利和合规服务的强劲需求，推动了稳健的收入增长和改善的可见性。PEO 部门的表现提供了多样化和稳定性，帮助抵消保险等更具周期性或利率敏感领域的波动，并强化了公司为寻求全方位人力资源解决方案的小型和中型雇主提供的价值主张。</p>
</div><h2>Increased Earnings Expectations</h2>
<div class="lb-trans"><h2>提高盈利预期</h2>
</div><p>Despite some areas of softness, Paychex raised its earnings outlook. Adjusted diluted earnings per share are now expected to grow between 10–11%, nudging the range higher from the prior 9–11% outlook. While GAAP diluted EPS for the quarter dipped 4% to $1.10, adjusted diluted EPS rose 11% to $1.26, reflecting strong underlying performance after excluding integration and other non-recurring items. The higher guidance signals management’s confidence that operational efficiencies and synergy realization will more than offset current headwinds.</p>
<div class="lb-trans"><p>尽管某些领域存在疲软，药明康德提高了其盈利展望。调整后的稀释每股收益预计将增长 10-11%，将范围从之前的 9-11% 上调。尽管本季度 GAAP 稀释每股收益下降 4% 至 1.10 美元，但调整后的稀释每股收益增长 11% 至 1.26 美元，反映出在排除整合和其他非经常性项目后强劲的基础表现。更高的指引表明管理层对运营效率和协同实现将超过当前逆风的信心。</p>
</div><h2>Softer Revenue Per Client</h2>
<div class="lb-trans"><h2>每位客户的收入疲软</h2>
</div><p>One concern flagged on the call was softer-than-expected revenue per client. Management attributed this mainly to smaller deal sizes and lower initial product attachment at the point of sale. While the client base remains solid, capturing more wallet share per client has proved challenging in the current environment. Paychex aims to address this by enhancing cross-sell efforts, improving front-line sales execution, and leveraging its AI-driven tools to demonstrate more value and encourage clients to adopt a broader suite of services over time.</p>
<div class="lb-trans"><p>电话会议上提到的一个担忧是每位客户的收入低于预期。管理层将此主要归因于较小的交易规模和销售时初始产品附加率较低。尽管客户基础依然稳固，但在当前环境中，获取每位客户更多的消费份额已证明具有挑战性。药明康德旨在通过增强交叉销售努力、改善前线销售执行以及利用其人工智能驱动的工具来展示更多价值，鼓励客户逐步采用更广泛的服务组合来解决这一问题。</p>
</div><h2>Challenges in Management Solutions</h2>
<div class="lb-trans"><h2>管理解决方案中的挑战</h2>
</div><p>Within Management Solutions, which remains a core revenue driver, revenue per client growth was also slightly softer due to the same mix of smaller deals and less product attachment upfront. This suggests that while demand for basic payroll and HR services is healthy, clients are being more cautious about layering on additional modules at the outset. Investors will be watching whether Paychex can reinvigorate upselling in this segment and convert initial relationships into deeper, higher-margin engagements as economic conditions evolve.</p>
<div class="lb-trans"><p>在管理解决方案中，作为核心收入驱动因素，每位客户的收入增长也因同样的小交易和前期产品附加较少而略显疲软。这表明，尽管对基本薪资和人力资源服务的需求健康，但客户在初期对附加更多模块持谨慎态度。投资者将关注药明康德是否能够在这一领域重新激活追加销售，并将初始关系转化为更深入、更高利润的合作关系，随着经济条件的演变。</p>
</div><h2>Paycor Growth Concerns</h2>
<div class="lb-trans"><h2>Paycor 增长担忧</h2>
</div><p>Although the Paycor integration is delivering synergy benefits, Paycor’s own organic growth has come in a bit below prior expectations, with estimated growth of 8–9%. Management described the situation as complex, citing integration-related disruption and client movement as contributing factors. While this slightly slower trajectory is a watch item, Paychex emphasized that the long-term strategic logic of the deal remains intact, and that harmonizing platforms and go-to-market strategies should ultimately support healthier, more sustainable growth from the combined entity.</p>
<div class="lb-trans"><p>尽管 Paycor 整合正在带来协同效益，但 Paycor 自身的有机增长略低于之前的预期，预计增长为 8-9%。管理层将情况描述为复杂，指出整合相关的干扰和客户流动是导致因素。尽管这一略微放缓的轨迹值得关注，但药明康德强调交易的长期战略逻辑依然完好，协调平台和市场策略最终应支持合并实体的更健康、更可持续的增长。</p>
</div><h2>Insurance Agency Performance Drag</h2>
<div class="lb-trans"><h2>保险代理表现拖累</h2>
</div><p>The insurance agency business was a notable drag on results, pressured by weaker workers’ compensation rates and lower volumes in health and benefits. These market-driven headwinds reduced revenue and tempered overall segment performance. While not central to the Paychex story, the insurance unit’s softness underscores the company’s exposure to rate environments and benefits trends, and reinforces the importance of the higher-growth PEO and technology-led HR services to drive overall company performance.</p>
<div class="lb-trans"><p>保险代理业务对业绩造成了显著拖累，受到工人赔偿率疲软和健康福利业务量下降的压力。这些市场驱动的逆风减少了收入，并抑制了整体业务部门的表现。虽然这并不是 Paychex 故事的核心，但保险部门的疲软凸显了公司对费率环境和福利趋势的暴露，并强化了高增长的 PEO 和技术驱动的人力资源服务在推动整体公司业绩方面的重要性。</p>
</div><h2>Guidance and Forward-Looking Outlook</h2>
<div class="lb-trans"><h2>指引与前瞻展望</h2>
</div><p>Looking ahead, Paychex reaffirmed its fiscal 2026 outlook and expressed confidence in its trajectory. Management expects around $100 million in Paycor-related cost synergies for the year and continues to target revenue synergies from cross-selling and platform integration. Adjusted diluted EPS growth is now projected at 10–11%, supported by 18% revenue growth this quarter, 21% growth in Management Solutions revenue, and a 21% increase in adjusted operating income. The company sees its AI initiatives, including the knowledge mesh system and GenAI compliance platform, as key levers for future efficiency gains and client value creation, positioning Paychex for durable growth despite near-term pressure in certain lines of business.</p>
<div class="lb-trans"><p>展望未来，Paychex 重申了其 2026 财年的展望，并对其发展轨迹表示信心。管理层预计今年与 Paycor 相关的成本协同效应约为 1 亿美元，并继续瞄准通过交叉销售和平台整合实现的收入协同效应。调整后的稀释每股收益增长现已预计为 10-11%，得益于本季度 18% 的收入增长、管理解决方案收入的 21% 增长，以及调整后营业收入的 21% 增加。公司认为其人工智能举措，包括知识网格系统和 GenAI 合规平台，是未来提高效率和创造客户价值的关键杠杆，使 Paychex 在某些业务线面临短期压力的情况下仍能实现可持续增长。</p>
</div><p>In summary, Paychex’s earnings call mixed strong execution with measured realism about current challenges. Revenue and adjusted profits are growing at a healthy clip, the Paycor integration is delivering ahead-of-plan synergies, and AI investments are beginning to reshape operations. At the same time, softer revenue per client, slightly underwhelming Paycor growth, and insurance headwinds remain areas to monitor. Overall, the tone was optimistic, with management leaning on innovation and integration benefits to support continued earnings growth and long-term shareholder value.</p>
<div class="lb-trans"><p>总之，Paychex 的财报电话会议将强劲的执行力与对当前挑战的审慎现实相结合。收入和调整后的利润以健康的速度增长，Paycor 的整合超出计划交付了协同效应，人工智能投资也开始重塑运营。同时，客户每单位收入的疲软、Paycor 增长略显乏力以及保险业务的逆风仍然是需要关注的领域。总体而言，语气乐观，管理层依靠创新和整合带来的好处来支持持续的盈利增长和长期的股东价值。</p>
</div>

沛齐的财报电话会议重点强调了增长、人工智能和协同效应